Compare Abeona Therapeutics Inc (ABEO) vs Prologis Inc (PLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Prologis Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Prologis Inc trades at $140.68 (market cap $133.89B). The key difference: Prologis Inc is far larger — about 358.6× Abeona Therapeutics Inc's market cap, and Prologis Inc pays a 2.98% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PLD | |
|---|---|---|
Market Cap | $373.32M | $133.89B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $148.74 |
52-Week Low | $4.17 | $104.08 |
Enterprise Value | $228.22M | $167.77B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Prologis (PLD) trades at $143.61, up 2.98% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 41.54% net income margin and a $1.07 dividend payment scheduled for June 30, 2026. Recent news highlights a rejected $16.6 billion takeover bid for Segro, indicating aggressive growth ambitions. Cash flow trends remain volatile, with 2025 net cash flow negative at -$172.94 million, though operating cash flow stays robust at $5.01 billion.
Outlook is positive with a consensus price target of $155.20, offering 8% upside. Risks include rising debt-to-asset ratio (37.2% in 2025) and macroeconomic sensitivity. The bullish analyst consensus (57% buy ratings) supports growth from data center expansion and rent spreads, but investors should monitor leverage and acquisition integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
